In many ways, the Obama administration’s new plan to map the human brain has its origins in the work of Brenda Milner, the neuropsychologist whose detailed observations of an amnesia patient in the 1950s showed how memory is rooted in specific regions of the brain.
"Prior to Brenda Milner’s discoveries, many behaviorists and some cognitive psychologists followed the lead of Freud and Skinner in abandoning biology as a useful guide to the study of memory,” the Nobel laureate Dr. Eric Kandel wrote in his memoir, “In Search of Memory.” “Milner’s work changed all that.”
Two Harvard Stem Cell Institue (HSCI) researchers - a stem cell biologist and a practicing cardiologist at Brigham and Women's Hospital - have identified a protein in the blood of mice and humans that may prove to be the first effective treatment for the form of age-related heart failure that affects millions of Americans.
When the protein, called GDF-11, was injected into old mice, which develop thickened heart walls in a manner similar to aging humans, the hearts were reduced in size and thickness, resembling the healthy hearts of younger mice.
A large body of research has linked late-life dpression to social isolation, poorer heatlh and an increased risk of death. Now, a new study finds that depression is associated wtih subsequent vascular dementia and Alzheimer's disease, conditions poised to expand dramatically with the aging population.
Massachusetts General Hospital (MGH) investigators have determined one of the recently identified genes contributing to the risk of late-onset Alzheimer's disease regulates the clearance of the toxic amyloid beta (A-beta) protein that accumulates in the brains of patients with the disease. In their report receiving advance online publication in Neuron, the researchers describe a protective variant of the CD33 gene that promotes clearance of A-beta from the brain.
Alzheimer's Association Advocacy Forum keynote speaker Dr. Francis Collins, director of the National Institutes of Health (NIH), provided attendees at Tuesday's General session with a dose of good news for Alzheimer's research during a time when optimism about financial resources may be in short supply.
Collins announced - in what he termed a unique step - that he has designated $40 million from his fiscal year 2013 director's budget for Alzheimer's research by scientists who recently submitted applications at the request of the National Institute on Aging.
As her mother and father edged toward dementia, Nancy D'Auria kept a piece of paper in her wallet listing their medications.
It had the dosages, the time of day each should be taken and a check mark when her folks, who live 10 miles away, assured her the pills had been swallowed.
"I work full time so it was very challenging," said D'Auria, 63, of West Nyack.
Now she has an app for that. With a tap or two on her iPhone, D'Auria can access a "pillbox" program that keeps it all organized for her and other relatives who share in the caregiving and subscribe to the app.
A gerontologist with close to 30 years of experience, Pillemer, who is director of the Cornell Institute for Translational Research on Aging, realized that his research was "entirely focused on older people as problems."
The NIH Brain Resaerch through Advancing Neurotechnologies (BRAIN) Initiative is part of a new Presidential focus aimed at revolutionizing our understanding of the human brain. By accelerating the development and application of innovative technologies, researchers will be able to produce a revolutionary new dynamic picture of the brain that, for the first time, shows how individual cells and complex neural circuits interact in both time and space.
A study in the Journal of the American Medical Association Neurology suggests that controlling or preventing risk factors, such as hypertension, earlier in life may limit or delay the brain chnages associated with Alzheimer's disease and other age-related neurological deterioration.
The Food and Drug Administration plans to loosen the rules for approving new treatments for Alzheimer's disease.
Drugs in clinical trial would qualify for approval if people at very early stages of the disease subtly improved their performance on memory or reasoning tests, even before they developed any obvious impairments. Companies would not have to show that the drugs improved daily, real-world functioning.